Webinar: Anemia Management Across the Spectrum of CKD: Real-World Challenges, Evolving Solutions

In this webinar, we discuss the epidemiology of anemia in DD- and NDD-CKD, exploring data from real world clinical practices, particularly from the Dialysis Outcomes and Practice Patterns Study (DOPPS) and Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps). We highlight the current challenges to translate current recommendations to clinical practice, and how this may impact the proposition of patient receiving treatment and achieving the recommended targets in anemia. Presenting an up-to-date survey of global trial data, we summarize recent advances in the field of anemia treatment that may change the way this condition will be managed in the future.  Finally, regional panelists will discuss their real-world perspectives on current treatment gaps and how emerging therapies may ameliorate these conditions.  

The agenda for this program is as follows:
  • Managing Anemia of CKD – How are we Doing, What are the Challenges- Speaker: Bruce Robinson (USA)
  • HIF PH Inhibitor - The Dawn of a New Age in Anemia Treatment - Speaker: Steven Fishbane (USA)
  • Roundtable Discussion: Global Perspectives - Panelists: Aleix Cases (Spain), Steven Fishbane (USA), Masaomi Nangaku (Japan), Roberto Pecoits-Filho (Brazil), Li Zuo (China)

Developed in partnership with Arbor Research Collaborative for Health

Supported by educational grants from AstraZeneca Pharmaceuticals

Please login or create an account to complete your evaluation and download your certificate. 

Target Audience

  • Physicians

Learning Objectives

Upon completion of this activity you will be better able to:

  • Review the global epidemiology of CKD anemia and real-world practice patterns across geographies and populations
  • Identify potential limitations and challenges in the current management paradigm that may be associated to under-treatment and under-achievement of targets 
  • Analyze data from recent trials across the spectrum of CKD and discuss how new treatment strategies may change the future approach to anemia management
  • Describe the current scenario of CKD anemia and how new therapies may impact the way anemia is managed and how outcomes may be impacted in the future
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
Course opens: 
12/01/2020
Course expires: 
02/04/2021
Cost:
$0.00
Rating: 
0
Faculty Disclosures:

Bruce Robinson, MD, MS, FACP
Arbor Research Collaborative for Health
Ann Arbor, MI

Steven Fishbane, MD
Chief of Nephrology
Northwell Health
Greak Neck, NY
Disclosure: Honoraria and research funding: AstraZeneca, Fibrogen, Akebia

Li Zuo, MD
Peking University People's Hospital
Beijing, China

Masaomi Nangaku, MD, PhD
Vice Dean/Professor
University of Tokyo Graduate School of Medicine
Tokyo, Japan
Disclosure: Honoraria, Research grant: Chugaii, Tori, JT
Honoraria, Consulting fee, Research grant: Boehringer Ingelheim, Tanabe-Mitsubishi, Daiichi-Sankyo, Astellas, Kyowa-Kirin
Honoraria: Astra Zeneca

Aleix Cases, MD, PhD
Associate Professor
University of Barcelona
Barcelona, Spain  
Disclosure:
Consulting fees: Novo Nordisk, Astellas, Vifor Pharma, GSK, Astra Zeneca
Honoraria: Bayer, Novo Nordisk, Astellas, Astra Zeneca

Roberto Pecoits-Filho, MD, PhD, FACP, FASN
Senior Research Scientist
Arbor Research Collaborative for Health
Ann Arbor, MI
Disclosure: Has no financial relationships with commercial interest(s).

Planner Disclosures:

Jessica Joseph, MBA
National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with commercial interest(s). 

Justin Albert, BA
DOPPS Program Director
Arbor Research
Ann Arbor, MI
Disclosure: Has no financial relationships with commercial interest(s). 

Lauren Kane, MPH
Project Coordinator
Arbor Research
Ann Arbor, MI
Disclosure: Has no financial relationships with commercial interest(s). 

Reviewer Disclosures:

Kelly Beers, DO
Assistant Professor 
Albany Medical College
Albany, NY
Disclosure: Has no financial relationships with commercial interest(s).

Sanjeev Shah, MD
Assistant Professor of Clinical Medicine
University of Pennsylvania
Philadelphia, PA
Disclosure: Has no financial relationships with commercial interest(s).
 

In support of improving patient care, the National Kidney Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician

The National Kidney Foundation designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance

Price

Cost:
$0.00
Please login or register for a PERC account to take this course.